Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Haemonetics Corporation, a medical technology company based in Braintree, MA, filed its quarterly report for the three-month period ended July 4, 1998. This fiscal quarter included 14 weeks due to the company's 53-week fiscal year structure for 1999. The company primarily manufactures and sells blood management systems and disposable products.
Key Financial Metrics
| Metric | Q1 1999 (Ended July 4, 1998) | Q1 1998 (Ended June 28, 1997) |
|---|---|---|
| Net Revenues | $71,996,000 | $79,485,000 |
| Gross Profit | $35,970,000 (50.0% margin) | $37,088,000 (46.7% margin) |
| Operating Income | $7,303,000 (10.1% margin) | $11,448,000 (14.4% margin) |
| Net Income (Continuing Ops) | $4,957,000 | $7,717,000 |
| Net Income (Total) | $4,900,000 | $6,481,000 |
| Diluted EPS | $0.184 | $0.243 |
| Cash from Operations | $10,890,000 | ($6,224,000) |
| Net Debt | $39,673,000 | $49,288,000 |
| Working Capital | $121,258,000 | $112,792,000 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 9.4% year-over-year. Management attributes this to unfavorable foreign exchange rates and the absence of a non-recurring $7.4 million order from the prior year. Excluding these factors, revenues would have increased 6.0%.
- Equipment Sales Drop: Equipment revenues fell 69.1%, primarily due to the lack of a $6.0 million plasma equipment shipment to China that occurred in the prior year.
- Margin Expansion: Despite lower revenues, gross profit margin improved to 50.0% from 46.7%, driven by lower product costs which offset unfavorable currency effects.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 20.0% to $24.9 million. Approximately $2.6 million of this increase was a provision for receivables related to a dispute with the American Red Cross.
- Cash Flow Improvement: Operating cash flow swung from a $6.2 million outflow in the prior year to a $10.9 million inflow, aided by a $7.7 million income tax refund and improved receivable collections.
- Debt Reduction: Net debt decreased by $9.6 million to $39.7 million as the company utilized operating cash to pay down borrowings.
Guidance, Outlook, and Risks
- Discontinued Operations: The company announced the discontinuation of its Blood Bank Management Services (BBMS) business. A $2.7 million operating loss for BBMS was charged to a reserve established in the previous quarter.
- Year 2000 Compliance: Management believes its Y2K compliance plan is prudent and costs will not be material to financial results. However, they noted uncertainty regarding the compliance of external vendors, particularly outside the U.S.
- Tax Rate: The effective tax rate for the quarter was 35.0%, and the annualized rate for fiscal 1999 is expected to remain at approximately 35%.
- Share Repurchases: The company does not expect to repurchase shares during the current fiscal year, contrasting with the $5.6 million spent on buybacks in the prior year's quarter.
- Accounting Changes: The company adopted SFAS No. 130 for comprehensive income reporting. It is evaluating the impact of SFAS No. 133 regarding derivative instruments, with adoption expected in fiscal years beginning after June 15, 1999.
Investor Verification Checklist
- Verify the status and resolution of the dispute with the American Red Cross regarding the $2.6 million receivable provision.
- Confirm the timeline and financial impact of the divestiture of the Blood Bank Management Services (BBMS) unit.
- Monitor the company's assessment of external vendor Year 2000 compliance, particularly for international supply chains.
- Review future equipment sales pipelines to determine if the $6.0 million China shipment was truly non-recurring or if similar large orders are anticipated.
- Track the impact of foreign currency fluctuations on future gross margins, given the 67% international sales mix.